Laurie Toich, Associate Editor

Many neuroendocrine cancers may be misdiagnosed without molecular pathway mapping.

A report from the Center for Medicare & Medicaid Services outlines projected health care spending between 2017 and 2026.

There are significant unmet clinical needs among patients with amyotrophic lateral sclerosis.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

New antiretroviral combination will be accessible to patients with HIV/AIDS in countries with limited resources.

Adolescent and young adult cancer survivors have a higher rate of heart disease, infertility, and cancer recurrence.

An experimental antiviral drug shows promise fighting multiple infectious diseases.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Federal judge finds that sofosbuvir (Sovaldi) and ledipasvir/sofosbuvir (Harvoni) do not infringe on Merck patents.

Researchers discover underlying reason why patients with Huntington's disease have a significantly lower risk of cancer.

Investigational small molecule drug may be able to treat herpes and HIV.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

A higher number of patients with ulcerative colitis treated with apremilast (Otezla) achieved clinical remission.

Combining oncolytic viruses and immunotherapies may fight cancer more effectively.

Treatment with durvalumab (Imfinzi) reduces the risk of disease progression among patients with non-small cell lung cancer.

The FDA recently approved durvalumab (Imfinzi) for the treatment of patients with stage 3 non-small cell lung cancer (NSCLC) whose tumors are unresectable and whose disease has not progressed following treatment with chemoradiation.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Crystalized dolutegravir may be able to reach viral reservoirs and cure HIV.

Lorlatinib was designed to bypass non-small cell lung cancer mutations that promote drug resistance

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

A popular multiple sclerosis drug may increase the risk of a potentially-fatal brain infection.

Less serious adverse events remain a concern for patients treated for chronic diseases.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.